Raps (rivaroxaban in antiphospholipid syndrome): A prospective randomised controlled phase II/III clinical trial of rivaroxaban vs. warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE

Category Primary study
ConferenceJournal of Thrombosis and Haemostasis
Year 2015
This article has no abstract
Epistemonikos ID: 6ddeaa95b3654fd519630a4215e93b12a05ff508
First added on: Apr 30, 2026